Hyperuricaemia - febuxostat: review decision - October 2011

Review of NICE Technology Appraisal Guidance no. 164; Febuxostat for the management of hyperuricaemia in people with gout

The Institute proposed that the guidance should be transferred to the ‘static guidance list’ for Technology Appraisals.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

This page was last updated: 03 October 2011